New Zealand has two committees that perform key roles in relation to drug policy and classification.
Inter-Agency Committee on Drugs (IACD)
The Inter-Agency Committee on Drugs (IACD) ensures that policies and programmes developed by government agencies are consistent and mutually supportive.
Expert Advisory Committee on Drugs (EACD)
The Misuse of Drugs Act 1975 (The Act) controls the supply of drugs by classifying drugs based on the risk of harm a drug poses to individuals or to society by their misuse.
The Expert Advisory Committee on Drugs (EACD) was established by the Misuse of Drugs Amendment Act 2000 to provide expert advice to the Minister of Health (the Minister) regarding drug classification issues.
The EACD is an advisory body that only makes recommendations to the Minister. It is the role of the Minister to decide whether to put forward any recommendations to Parliament for decision.
- conducts reviews of controlled drugs and other narcotic or psychotropic substances
- recommends to the Minister whether and how such substances should be classified under the Act
- increases public awareness of its work by (for instance) releasing papers, reports and recommendations.
The Act requires the EACD to consist of up to 11 members. The Committee must comprise up to:
- five people who, between them, have appropriate expertise in:
- drug and alcohol treatment
- community medicine
- three people employed in the Public Service who between them have appropriate expertise in:
- public health
- the appropriateness and safety of pharmaceuticals and their availability to the public
- border control.
- Also required are:
- one Police employee
- one employee of the Ministry of Justice who has appropriate expertise in matters relating to the justice system
- one person representing the views of consumers of drug treatment services.
The EACD reconvened in October 2014. The current members are:
- Dr John Ashton (Chair) – pharmacology
- Dr Paul Fitzmaurice – toxicology
- Dr Vicki Macfarlane – drug and alcohol treatment
- Dr Jaki Horn – psychology
- Dr Patrick O’Connor – community medicine
- Ms Lynette Knox – consumer representative
- Dr Richard Jaine –public health/safety of pharmaceuticals and their availability to the public (Ministry of Health)
- Mr James Bamford – border control
- Detective Superintendent Gregory Williams – New Zealand Police
- vacant – Ministry of Justice.
Drug classification process
The Act requires the classification of controlled drugs to be based on the risk of harm to individuals or society. The EACD is required to advise the Minister on a range of specific criteria for each drug. These include:
- the likelihood or evidence of drug abuse, including the prevalence of the drug, levels of consumption, drug seizure trends, and the potential appeal to vulnerable populations
- the specific effects of the drug, including pharmacological, psychoactive, and toxicological effects
- the risks, if any, to public health
- the therapeutic value of the drug, if any
- the potential for use of the drug to cause death
- the ability of the drug to create physical or psychological dependence
- the international classification and experience of the drug in other jurisdictions
- any other matters that the Minister considers relevant.
The Committee is administered by a Secretariat comprised of Ministry of Health officials and advisers, as required. The Secretariat’s contact details are:
c/o Regulatory Practice and Analysis
Ministry of Health
PO Box 5013
More information on the criteria for classifying drugs, the role of the EACD and the Minister of Health, and the classification process is contained in sections 3A to 5AA of the Act. Go to the Misuse of Drugs Act 1975 on the New Zealand Legislation website to learn more.
26 October 2016 meeting:
- Agenda – redacted under sections 9(2)(g)(ii) under the Official Information Act 1982 (Word, 64 KB)
- Minutes – redacted under sections 9(2)(ba) and 9(2)(g)(ii) under the Official Information Act 1982 (Word, 139 KB)
- Response to EACD queries on Cannabidiol (CBD) – redacted under section 6(b)(i) and 9(2)(ba)(i) of the Official Information Act 1982 (pdf, 618 KB)
- Additional notes to CBD paper – redacted under section 9(2)(ba)(i) under the Official Information Act 1982 (Word, 18 KB)
- Letter of advice to the Minister from the EACD – redacted under section 9(2)(g)(ii) of the Official Information Act 1982 (pdf, 978 KB)
- Advice from the Expert Advisory Committee on Drugs on the Classification of Cannabidiol - redacted under section 9(2)(g)(i) of the Official Information Act (Word, 188.45)
27 April 2016 meeting:
- Agenda (Word, 71 KB)
- Minutes – redacted under section 9(2)(ba) of the Official Information Act 1982 (Word, 90 KB)
- Submission on Cannabidiol (CBD) (Word, 671 KB)
- Classification of Cannabidiol discussion document – redacted under section 9(2)(a) of the Official Information Act 1982 (PDF, 400 KB)
- Interest in ‘Medicinal Cannabis’ and the Classification of Cannabidiol (Word, 15 KB)
7 October 2015 meeting:
- Agenda (Word, 70 KB)
- Minutes – redacted under section 9(2)(ba) of the Official Information Act 1982 (Word, 81 KB)
16 April 2015 meeting:
- Agenda (Word, 70 KB)
- Minutes – redacted under section 9(2)(ba) of the Official Information Act 1982 (Word, 76 KB)
23 October 2014 meeting: